share_log

Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $43

Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $43

派珀·桑德勒维持对Supernus Pharmicals的增持,将目标股价提高至43美元
Benzinga ·  2023/11/09 14:56

Piper Sandler analyst David Amsellem maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and raises the price target from $42 to $43.

派珀·桑德勒分析师戴维·阿姆塞勒维持Supernus Pharmicals(纳斯达克股票代码:SUPN)增持 “增持”,并将目标股价从42美元上调至43美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发